https://bsd.neuroinf.jp/w/index.php?action=history&feed=atom&title=Levormeloxifene
Levormeloxifene - 版の履歴
2026-04-12T11:22:26Z
このウィキのこのページに関する変更履歴
MediaWiki 1.43.8
https://bsd.neuroinf.jp/w/index.php?title=Levormeloxifene&diff=49896&oldid=prev
WikiSysop: 1版 をインポートしました
2025-03-18T10:32:17Z
<p>1版 をインポートしました</p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="ja">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← 古い版</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年3月18日 (火) 19:32時点における版</td>
</tr><tr><td colspan="4" class="diff-notice" lang="ja"><div class="mw-diff-empty">(相違点なし)</div>
</td></tr>
<!-- diff cache key wiki-mw_:diff:1.41:old-49895:rev-49896 -->
</table>
WikiSysop
https://bsd.neuroinf.jp/w/index.php?title=Levormeloxifene&diff=49895&oldid=prev
bsd>Ozzie10aaaa: Cleaned up using AutoEd
2025-01-18T15:23:12Z
<p>Cleaned up using <a href="/w/index.php?title=WP:AutoEd&action=edit&redlink=1" class="new" title="WP:AutoEd (存在しないページ)">AutoEd</a></p>
<p><b>新規ページ</b></p><div>{{Short description|Chemical compound}}<br />
{{Drugbox<br />
| Verifiedfields = changed<br />
| Watchedfields =<br />
| verifiedrevid = 462091315<br />
| IUPAC_name = 1-(2-[4-[(3''R'',4''R'')-7-Methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2''H''-chromen-4-yl]phenoxy]ethyl)pyrrolidine<br />
| image = Levormeloxifene.svg<br />
| width = 225px<br />
<br />
<!--Clinical data--><br />
| tradename =<br />
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --><br />
| pregnancy_US = <!-- A / B / C / D / X --><br />
| pregnancy_category =<br />
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --><br />
| legal_CA =<br />
| legal_UK =<br />
| legal_US =<br />
| legal_status =<br />
| routes_of_administration =<br />
<br />
<!--Pharmacokinetic data--><br />
| bioavailability =<br />
| protein_bound =<br />
| metabolism =<br />
| elimination_half-life =<br />
| excretion =<br />
<br />
<!-- Identifiers --><br />
| CAS_number_Ref = {{cascite|changed|??}}<br />
| CAS_number = 78994-23-7<br />
| CAS_supplemental =<br />
| class =<br />
| ATC_prefix =<br />
| ATC_suffix =<br />
| ATC_supplemental =<br />
| PubChem = 35805<br />
| IUPHAR_ligand =<br />
| DrugBank_Ref =<br />
| DrugBank =<br />
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}<br />
| ChemSpiderID = 32935<br />
| UNII_Ref = {{fdacite|correct|FDA}}<br />
| UNII = 9512UKZ352<br />
| KEGG =<br />
| ChEBI =<br />
| ChEMBL_Ref = {{ebicite|correct|EBI}}<br />
| ChEMBL = 301327<br />
| synonyms = Levomeloxifene; 6720-CDRI; NNC-460020<br />
<br />
<!--Chemical data--><br />
| C=30 | H=35 | N=1 | O=3<br />
| SMILES = O(c1ccc(cc1)[C@@H]3c4c(OC([C@H]3c2ccccc2)(C)C)cc(OC)cc4)CCN5CCCC5<br />
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}<br />
| StdInChI = 1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1<br />
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}<br />
| StdInChIKey = XZEUAXYWNKYKPL-WDYNHAJCSA-N<br />
}}<br />
<br />
'''Levormeloxifene''' ({{abbrlink|INN|International Nonproprietary Name}}; developmental code names '''6720-CDRI''', '''NNC-460020''') is a [[selective estrogen receptor modulator]] (SERM) which was being developed as an alternative to [[hormone replacement therapy (menopause)|estrogen replacement therapy]] for the treatment and prevention of [[menopause|postmenopausal]] [[Osteoporosis|bone loss]] but did not complete development and hence was never marketed.<ref name="AdisInsight">{{Cite web | url=http://adisinsight.springer.com/drugs/800000737 |title = Levormeloxifene - AdisInsight}}</ref> The development was stopped because of a high incidence of [[gynecological]] [[side effect]]s during [[clinical trial]]s.<ref name="pmid16532904">{{cite journal | vauthors = Ravn P, Nielsen TF, Christiansen C | title = What can be learned from the levormeloxifene experience? | journal = Acta Obstet Gynecol Scand | volume = 85 | issue = 2 | pages = 135–42 | year = 2006 | pmid = 16532904 | doi = 10.1080/00016340500345691| s2cid = 12872469 | doi-access = free }}</ref> Levormeloxifene is the [[dextrorotation and levorotation|levorotatory]] [[enantiomer]] of [[ormeloxifene]], which, in contrast, has been marketed, though rather as a [[hormonal contraceptive]].<br />
<br />
==See also==<br />
* [[List of selective estrogen receptor modulators]]<br />
<br />
==References==<br />
{{Reflist|2}}<br />
<br />
==External links==<br />
* [http://adisinsight.springer.com/drugs/800000737 Levormeloxifene - AdisInsight]<br />
<br />
{{Estrogen receptor modulators}}<br />
<br />
[[Category:Abandoned drugs]]<br />
[[Category:Benzopyrans]]<br />
[[Category:Ethers]]<br />
[[Category:1-Pyrrolidinyl compounds]]<br />
[[Category:Selective estrogen receptor modulators]]<br />
<br />
<br />
{{genito-urinary-drug-stub}}</div>
bsd>Ozzie10aaaa